Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: Novel marker genes and prediction model using the expression levels

Breast Cancer

Volumn 19, Issue 1, 2012, Pages 37-45

  Sano, Hiroshi ^a   Wada, Satoru ^a   Eguchi, Hidetaka ^a   Osaki, Akihiko ^a   Saeki, Toshiaki ^a   Nishiyama, Masahiko ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Marker gene; Neoadjuvant chemotherapy; Response prediction

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN;

ADULT; AGED; ANXA1 GENE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; DUSP2 GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MARKER GENE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PRKCA GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERPINA3 GENE; TREATMENT DURATION; TUMOR VOLUME;

ADULT; AGED; ANNEXINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DUAL SPECIFICITY PHOSPHATASE 2; EPIRUBICIN; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; NEOADJUVANT THERAPY; PROTEIN KINASE C-ALPHA; REGRESSION ANALYSIS; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859787453     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0263-8     Document Type: Article

References (36)

1. Horiguchi J. New trends in primary systemic therapy for breast cancer. Breast Cancer 2010; Epub ahead of print, doi:10.1007/s12282-010-0243-4.
2. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet. 2009;373:1463-79.
3. Kinoshita T. Preoperative therapy: recent findings. Breast Cancer 2010; Epub ahead of print doi:10.1007/s12282-010-0227-4.
4. Untch M, von Minckwitz G. Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res. 2009;11:203.
5. Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast. 2009;18(Suppl 3):S137-40.
6. Beasley GM, Olson JA Jr. What's new in neoadjuvant therapy for breast cancer? Adv Surg. 2010;44:199-228.
7. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer - current status and future directions. Ann Oncol. 2009;20:1913-27.
8. Shenoy HG, Peter MB, Masannat YA, Dall BJ, Dodwell D, Horgan K. Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer. Surg Oncol. 2009;18:65-71.
9. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF. Neoadjuvant therapy for breast cancer. J Surg Oncol. 2010;101:283-91.
10. Munro AF, Cameron DA, Bartlett JM. Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene. 2010;29:5231-40.
11. Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11:266-74.
12. Marsh S, Liu G. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:381-7.
13. Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology. 2009;251:653-62.
14. Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, et al. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 2010;103:297-302.
15. Chuthapisith S, Eremin JM, Eremin O. Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (Review). Oncol Rep. 2008;20:699-703.
16. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, et al. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004;11:617-26. (Pubitemid 39045331)
17. Komatsu M, Hiyama K, Tanimoto K, Yunokawa M, Otani K, Ohtaki M, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther. 2006;5:767-75.
18. Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J, et al. Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data. Int J Oncol. 2006;28:1153-62.
19. Fumoto S, Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, et al. Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol. 2008;32:413-23. (Pubitemid 351188308)
20. Nishiyama M, Eguchi H. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:402-7.
21. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A. 2001;98:10787-92. (Pubitemid 32878698)
22. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41:101-21. (Pubitemid 32385884)
23. Rousseeuw PJ. Least median of squares regression. J Am Stat Assoc. 1984;79:871-80.
24. Turaga K, Acs G, Laronga C. Gene expression profiling in breast cancer. Cancer Control. 2010;17:177-82.
25. Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 2010; Epub ahead of print doi:10.1101/cshperspect.a003293.
26. Ou K, Yu K, Kesuma D, Hooi M, Huang N, Chen W, et al. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J Proteome Res. 2008;7:1518-28.
27. Bergman PJ, Gravitt KR, Ward NE, Beltran P, Gupta KP, O'Brian CA. Potent induction of human colon cancer uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism. Invest New Drugs. 1997;15:311-8. (Pubitemid 28098497)
28. Gravitt KR, Ward NE, Fan D, Skibber JM, Levin B, O'Brian CA. Evidence that protein kinase C-alpha activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells. Biochem Phamacol. 1994;48:375-81. (Pubitemid 24243981)
29. Chen Y, Yu G, Yu D, Zhu M. PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1. J Exp Clin Cancer Res. 2010;29:104.
30. Bermudez O, Pagès G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010;299:C189-202.
31. Baker C, Belbin O, Kalsheker N, Morgan K. SERPINA3 (aka alpha-1-antichymotrypsin). Front Biosci. 2007;12:2821-35.
32. Cimino D, Fuso L, Sfiligoi C, Biglia N, Ponzone R, Maggiorotto F, et al. Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Cancer. 2008;123:1327-38.
33. Pohl A, Lurje G, Manegold PC, Lenz HJ. Pharmacogenomics and -genetics in colorectal cancer. Adv Drug Deliv Rev. 2009;61:375-80.
34. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol. 2006;24:1883-91. (Pubitemid 46638987)
35. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF. Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet. 2006;51:155-60.
36. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927-33. (Pubitemid 44356853)